检索结果-南通市图书馆

Prevention of thromboembolic events after radical prostatectomy in patients with hereditary thrombophilia due to a factor V Leiden mutation by multidisciplinary coagulation management

引用

Asian Journal of Urology 2024年第1期11卷 42-47页

作者： Randi M.Pose sophie knipper Jonas Ekrutt Mara Kölker Pierre Tennstedt Hans Heinzer Derya Tilki Florian Langer Markus Graefen Martini-Klinik Prostate Cancer Centre University Hospital Hamburg-EppendorfGermany Department of Urology University Hospital Hamburg-EppendorfGermany Department of Hematology and Oncology University Medical Centre Hamburg-EppendorfHamburgGermany

Objective:To examine the perioperative impact of factor V Leiden mutation on thromboembolic events'risk in radical prostatectomy(RP)*** an incidence of about 5%,factor V Leiden mutation is the most common hereditary hypercoagulability among Caucasians and rarer in *** increased risk of thromboembolic events is three-to seven-fold in heterozygous and to 80-fold in homozygous ***:Within our prospectively collected database,we analysed 33006 prostate cancer patients treated with RP between December 2001 and December *** those,patients with factor V Leiden mutation were *** patients received individualised recommendation of haemostaseologists for perioperative *** complications(deep vein thrombosis and pulmonary embolism)were assessed during hospital stay,as well as according to patient reported outcomes within the first 3 months after ***:Overall,85(0.3%)patients with known factor V Leiden mutation were *** age was 65(interquartile range:61-68)*** was at least one thrombosis in 53(62.4%)patients and 31(36.5%)patients had at least one embolic event in their medical history before *** all 85 patients with factor V Leiden mutation,we experienced no thromboembolic complications within the first 3 months after ***:In our cohort of patients with factor V Leiden mutation,no thromboembolic events were observed after RP with an individualised perioperative coagulation management *** may reassure patients with this hereditary condition who are counselled for RP.

关键词： Prostatecancer Prostatectomy Factor V Leiden mutation Thromboembolism Thrombophilia

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Systematic evaluation of a holmium:yttrium-aluminum-garnet laser lithotripsy device with variable pulse peak power and pulse duration

引用

Asian Journal of Urology 2014年第1期1卷 60-65页

作者： Christopher Netsch sophie knipper Christian Tiburtius Andreas J.Gross Department of Urology Asklepios Hospital BarmbekHamburgGermany

Objective:The Holmium:yttrium-aluminum-garnet(Ho:YAG)laser is the standard lithotrite for *** paper is to evaluate a Ho:YAG laser with a novel effect function in vitro,which allows a real-time variation of pulse duration and pulse peak ***:Two types of phantom calculi with four degrees of hardness were made for fragmentation and retropulsion *** was analysed at 5(0.5 J/10 Hz),10(1 J/10 Hz),and 20(2 J/10 Hz)W in non-floating phantom calculi,retropulsion in an ureteral model at 10(1 J/10 Hz)and 20(2 J/10 Hz)W using floating phantom *** effect function was set to 25%,50%,75%,and 100%of the maximum possible effect function at each power *** outcomes:fragmentation(mm^3),the distance of retropulsion(cm);5 measurements for each ***:An increase of the effect feature(25%vs.100%),i.e.,an increase of pulse peak power and decrease of pulse duration,improved Ho:YAG laser *** effect was remarkable in soft stone composition,while there was a trend for improved fragmentation with an increase of the effect feature in hard stone *** increased with increasing effect function,independently of stone *** major limitations of the study are the use of artificial stones and the in vitro ***:Changes in pulse duration and pulse peak power may lead to improved stone fragmentation,most prominently in soft stones,but also lead to increased *** new effect function may enhance Ho:YAG laser fragmentation when maximum power output is limited or retropulsion is excluded.

关键词： Ureteroscopy Ho:YAG laser Lithotripsy Pulse peak power Pulse duration

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?

引用

Asian Journal of Urology 2021年第2期8卷 248-250页

作者： sophie knipper Gunhild von Amsberg Franziska Stolzenbach Thomas Steuber Matthias Heck Matthias Eiber Christoph Berliner Tobias Maurer Martini-Klinik Prostate Cancer Center University Hospital Hamburg-EppendorfHamburgGermany Martini-Klinik Prostate Cancer Center University Hospital Hamburg-EppendorfHamburgGermany Department of OncologyUniversity Hospital Hamburg-EppendorfHamburgGermany Martini-Klinik Prostate Cancer Center University Hospital Hamburg-EppendorfHamburgGermany Department of UrologyUniversity Hospital Hamburg-EppendorfHamburgGermany Department of Urology Technical University of MunichMunichGermany Department of Nuclear Medicine Technical University of MunichMunichGermany Department of Nuclear Medicine University Hospital Hamburg-EppendorfHamburgGermany

Dear editor,Since the introduction of radiotracer-labeled prostatespecific membrane antigen(PSMA)targeting positron emission tomography(PET),imaging of prostate cancer(PCa)improved drastically[1,2].Subsequently,metastases may be detected in earlier stages with possible implications on treatment planning[3].Here,we described the multimodal treatment approach on a young patient with newly diagnosed metastatic PCa conducted according to the results of repeated PSMAePET imaging.

关键词： metastatic cancer treatment

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer

引用

Asian Journal of Urology 2022年第1期9卷 69-74页

作者： Christa Babst Thomas Amiel Tobias Maurer sophie knipper Lukas Lunger Robert Tauber Margitta Retz Kathleen Herkommer Matthias Eiber Gunhild von Amsbergb Markus Graefen Juergen Gschwend Thomas Steuber Matthias Heck Department of Urology Technical University of MunichRechts der Isar Medical CenterMunichGermany Martini-Klinik Prostate Cancer Center HamburgGermany

Objective:Cytoreductive radical prostatectomy(cRP)has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer(mHSPC)to prevent local complications and potentially improve oncological *** this study,we examined the feasibility of a multimodal concept with primary chemohormonal therapy followed by cRP and analyzed prostate size reduction under systemic treatment,postoperative complication rates,as well as early postoperative ***:In this retrospective study,38 patients with mHSPC underwent cRP after primary chemohormonal therapy(3-monthly luteinising hormone-releasing hormone-analogue+six cycles 3-weekly docetaxel 75 mg/m2)at two centers between September 2015 and December ***:Overall,10(26%)patients had high volume and 28(74%)patients had low volume disease at diagnosis,according to CHAARTED *** prostate-specific antigen(PSA)decreased from 65 ng/mL(interquartile range[IQR]35.0-124.5 ng/mL)pre-chemotherapy to 1 ng/mL(IQR 0.3-1.7 ng/mL)*** gland volume was significantly reduced by a median of 50%(IQR 29%-56%)under chemohormonal therapy(p=0.003).Postoperative histopathology showed seminal vesicle invasion in 33(87%)patients and negative surgical margins in 17(45%)*** complications(Grade 3 according to Clavien-Dindo)were observed in 4(11%)patients within 30 *** was reached in 87%of patients after 1 month and in 92%of patients after 6 *** time to castration-resistance from begin of chemohormonal therapy was 41.1 months and from cRP was 35.9 *** PSA-nadir≤1 ng/mL versus>1 ng/mL was a significant predictor of time to castration-resistance after cRP(median not reached versus 5.3 months;p<0.0001).Conclusion:We observed a reduction of prostate volume under chemohormonal therapy going along with a low postoperative complication and high early continence ***,the oncologic benefit from cRP is still under evaluation.

关键词： Metastatic hormone-sensitive prostate cancer Chemohormonal therapy Cytoreductive radical prostatectomy Feasibility Prevent local complications Continence rate

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Primary lymphomas of the genitourinary tract:A population-based study

引用

Asian Journal of Urology 2020年第4期7卷 332-339页

作者： Carlotta Palumbo Elio Mazzone Francesco A.Mistretta sophie knipper Zhe Tian Paul Perrotte Francesco Montorsi Shahrokh F.Shariat Fred Saad Claudio Simeone Alberto Briganti Alessandro Antonelli Pierre I.Karakiewicz Cancer Prognostics and Health Outcomes Unit University of Montreal Health CenterMontrealQuebecCanada Urology Unit ASST Spedali Civili of BresciaDepartment of Medical and Surgical SpecialtiesRadiological Science and Public HealthUniversity of BresciaBresciaItaly Division of Experimental Oncology Unit of UrologyUrological Research Institute(URI)IRCCS San Raffaele Scientific InstituteMilanItaly Vita-Salute San Raffaele University MilanItaly Department of Urology European Institute of OncologyMilanItaly Martini Klinik University Medical Center Hamburg-EppendorfHamburgGermany Division of Urology University of Montreal Hospital Center(CHUM)MontrealQuebecCanada Department of Urology Comprehensive Cancer CenterMedical University of ViennaViennaAustria Department of Urology Weill Cornell Medical CollegeNew YorkNYUSA Department of Urology University of Texas SouthwesternDallasTXUSA Department of Urology Second Faculty of MedicineCharles UniversityPragCzech Republic Institute for Urology and Reproductive Health I.M.Sechenov First Moscow State Medical UniversityMoscowRussia

Objective:We performed a population-based analysis focusing on primary extranodal lymphoma of either testis,kidney,bladder or prostate(PGUL).Methods:We identified all cases of localized testis,renal,bladder and prostate primary lymphomas(PL)versus primary testis,kidney,bladder and prostate cancers within the Surveillance,Epidemiology,and End Results database(1998e2015).Estimated annual proportion change methodology(EAPC),multivariable logistic regression models,cumulative incidence plots and multivariable competing risks regression models were ***:The rates of testis-PL,renal-PL,bladder-PL and prostate-PL were 3.04%,0.22%,0.18%and 0.01%,*** with PGUL were older and more frequently *** rates significantly decreased for renal-PL(EAPC:5.6%;pZ0.004)and prostate-PL(EAPC:3.6%;pZ0.03).In multivariable logistic regression models,older ager independently predicted testis-PL(odds ratio[OR]:16.4;p<0.001)and renal-PL(OR:3.5;p<0.001),while female gender independently predicted bladder-PL(OR:5.5;p<0.001).In surgically treated patients,cumulative incidence plots showed significantly higher 10-year cancer-specific mortality(CSM)rates for testis-PL,renal-PL and prostate-PL versus their primary genitourinary *** multivariable competing risks regression models,only testis-PL(hazard ratio[HR]:16.7;p<0.001)and renal-PL(HR:2.52;p<0.001)independently predicted higher CSM ***:PGUL rates are extremely low and on the decrease in kidney and prostate but stable in testis and *** to primary genitourinary tumors,PGUL are associated with worse CSM for testis-PL and renal-PL but not for bladder-PL and prostate-PL,even after adjustment for other-cause mortality.

关键词： Bladder lymphoma Genitourinary neoplasm Genitourinary Primary extranodal lymphoma Prostate lymphoma Renal lymphoma Testis lymphoma Survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：